Asset Details
Do you wish to reserve the book?
Proof-of-concept trial of oncolytic poxvirus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Proof-of-concept trial of oncolytic poxvirus
Do you wish to request the book?
Proof-of-concept trial of oncolytic poxvirus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Proof-of-concept trial of oncolytic poxvirus
2011
Overview
JX-594 is a granulocyte-macrophage colony-stimulating factor-expressing oncolytic pox-virus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. Hwang et al. report the findings of a low-dose, mechanistic proof-of-concept clinical trial of JX-594 in 10 people with previously treated stage IV melanoma. The authors present evidence for JX-594 replication, oncolysis, and transgene expression. Replication was still evident after multiple cycles. The findings have implications for further clinical development of JX-594 and other transgene-armed oncolytic viruses.
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.